GEHC

GE HealthCare Technologies
D

GEHC

Arincen60/100B

GE HealthCare Technologies executives and insider trading

Peter J. Arduini bought 4,169 shares for 249,827 USD and sold 0 for 0 USD on the open market over the last twelve months.

Over the last twelve months GE HealthCare Technologies's insiders sold 0 shares for 0 USD in 0 sales on the open market, and bought 103,652 shares in 8 purchases.

Insiders over the last twelve months

Insider sales
0
Shares sold
—
Value sold
—
Insider purchases
8

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
0
0
3 months
0
742.16K USD
6 months
0
6.42M USD
1 year
0
6.42M USD
2 years
185.08K USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Peter J. Arduini CEOPresident, Chief Executive Officer & Director61——4,169——
H Lawrence Jr Culp Director———80,805——
Kevin Lobo Director———10,000——
James Saccaro Chief Financial Officer———3,310——
Frank R. Jimenez General Counsel & Corporate Secretary61——1,750——
Rodney F Hochman Director———1,618——
Watkin Phoebe L. Yang Director———1,000——
William J Stromberg Director———1,000——

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
22 May 2026Kevin LoboPurchase10,00064.18641.80K USD14,363Form 4
12 May 2026Rodney F HochmanPurchase1,61862.03100.36K USD1,618Form 4
8 May 2026Watkin Phoebe L. YangPurchase1,00063.0163.01K USD13,702Form 4
6 May 2026H Lawrence Jr CulpPurchase80,80561.885.00M USD151,207Form 4
6 May 2026William J StrombergPurchase1,00061.6961.69K USD15,330Form 4
1 May 2026James SaccaroPurchase3,31060.60200.59K USD87,471Form 4
30 Apr 2026Frank R. JimenezPurchase1,75060.45105.79K USD93,932Form 4
30 Apr 2026Peter J. ArduiniPurchase4,16959.93249.83K USD259,424Form 4
18 Feb 2025George Andrew NewcombSale2,00092.54185.08K USD7,462Form 4

Common questions about GE HealthCare Technologies's executives and insiders

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.